NextGen liquicore CTC comprehensive

What is a NextGen Liquicore CTC Comprehensive Test? 

The NextGen Liquicore CTC comprehensive test is an advanced blood test that uses liquid biopsy technology to detect and analyse circulating tumour cells (CTCs) in your bloodstream. This non-invasive test uses Next-Generation Sequencing (NGS) to examine the genetic makeup of cancer cells that have entered your blood circulation. 

The test helps detect microsatellite instability and monitor genetic changes in tumours, particularly for patients with colorectal cancer, endometrial cancer, and gastric cancer. 

What Does the NextGen Liquicore CTC Comprehensive Test Measure? 

This comprehensive test provides detailed information about your cancer through several key measurements: 

• Presence and count of circulating tumour cells - Detects cancer cells in your bloodstream and determines their number. 

• Genetic mutations and alterations - Analyses DNA changes that drive cancer growth using advanced sequencing technology. 

• Biomarkers for targeted therapy - Finds specific targets on cancer cells to guide personalised treatment decisions. 

• Treatment resistance patterns - Monitors how cancer cells evolve and develop resistance to current therapies. 

NextGen Liquicore CTC Comprehensive Test: Who Needs It and Why It's Done 

Who should get a NextGen Liquicore CTC Comprehensive Test? 

Your doctor may recommend this test if you belong to specific patient groups who can benefit from advanced genetic monitoring: 

• Patients with metastatic cancer - Especially those with breast cancer, prostate cancer, colorectal cancer, or lung cancer that has spread. 

• Patients receiving targeted therapy - To monitor treatment effectiveness and detect emerging resistance. 

• Patients unsuitable for tissue biopsy - When tumours are in difficult-to-access locations or biopsy poses health risks. 

• Patients in cancer remission - For early detection of cancer recurrence before symptoms appear. 

• Patients with suspected Lynch syndrome - Those with a family history of colorectal or endometrial cancers. 

Why is a NextGen Liquicore CTC Comprehensive Test done? 

This test provides real-time genetic information about your cancer through a simple blood draw. This enables your oncologist to make personalised treatment decisions and monitor disease progression safely and effectively. 

Importance of a NextGen Liquicore CTC Comprehensive Test 

The NextGen Liquicore CTC comprehensive test represents a significant advancement in cancer care, particularly valuable in India's evolving healthcare landscape. This test enables personalised medicine by identifying unique genetic mutations in your cancer, allowing doctors to select targeted therapies most likely to succeed. Unlike invasive tissue biopsies, this liquid biopsy requires only a blood sample, making it safer and repeatable for ongoing monitoring. 

The test provides comprehensive tumour profiling by analysing circulating cancer cells that represent the entire disease burden in your body, not just one tumour location. It can detect cancer recurrence earlier than traditional imaging methods, potentially allowing for timely intervention. For patients with MSI-positive cancers, the test informs immunotherapy decisions, which can significantly improve treatment outcomes with fewer side effects compared to conventional chemotherapy. 

NextGen Liquicore CTC Comprehensive Test Booking & Reports – Metropolis Healthcare India 

How to Book a NextGen Liquicore CTC Comprehensive Test? 

1. Simple Online Booking 
   Booking can be done through the Metropolis Healthcare App or website. Select the NextGen Liquicore CTC Comprehensive Test, choose a convenient time slot, and provide your address for a blood test at home. You can also visit the nearest Metropolis Lab if you prefer to give the sample directly at the lab. 
    
2. Safe Home Sample Collection 
   Our trained phlebotomists ensure the timely collection of your sample while strictly following all safety and hygiene protocols. 
    
3. Sample Tracking Updates 
   Stay informed at every step. From collection to testing, you can track your sample directly through the Metropolis Healthcare website. 
    
4. Accurate Laboratory Testing 
   Your sample is processed at our NABL & CAP accredited laboratories, where expert technicians ensure accurate results. 
    
5. Quick & Easy Reports 
   Receive your test reports promptly via email, WhatsApp, or by downloading them directly from the Metropolis Healthcare website or app. 

Is home sample collection for NextGen Liquicore CTC Comprehensive Test available near you? 

Yes, Metropolis Healthcare provides home blood sample collection for the NextGen Liquicore CTC comprehensive test. Our trained phlebotomists follow strict safety protocols while collecting your blood sample in the comfort of your home. This service eliminates the need for travel to the pathology lab and reduces exposure to infections, particularly important for cancer patients with compromised immune systems. 

How Long Does It Take to Get a NextGen Liquicore CTC Comprehensive Test Report? 

Reports are usually available after 10 days once the sample has reached the lab. 

Note: Reporting time may vary depending on your location. 

Where can I see or get NextGen Liquicore CTC comprehensive test results? 

Test results from Metropolis Healthcare can be accessed through multiple convenient channels. You can log in to the Metropolis website using your credentials or use the Metropolis Healthcare App to view and download your reports. Additionally, test reports are sent via email or WhatsApp, and you also have the option to collect a physical copy directly from the lab. 

Interpreting NextGen Liquicore CTC Comprehensive Test Results 

The following table provides guidance on understanding your test results and their clinical significance: 

Parameter	Reference Range	High Values May Indicate	Low/Negative Values May Indicate
CTC cells	Varies based on cancer type and stage	Active cancer, disease progression, or treatment resistance	Good treatment response or absence of detectable cancer cells

Conditions that May Affect NextGen Liquicore CTC Comprehensive Test Accuracy 

Several factors can influence your NextGen Liquicore CTC Comprehensive Test results and should be discussed with your healthcare provider: 

• Sample collection timing - Blood must be collected within 24 hours and maintained at proper temperature conditions. 

• Haemolysed or clotted blood samples - Can interfere with cell analysis and genetic sequencing. 

• Concurrent cancer treatments - Chemotherapy or radiation may temporarily reduce circulating tumour cell numbers. 

• Sample handling and storage - Improper temperature maintenance during transport can affect cell viability. 

• Insufficient sample volume - Less than the required 8-10ml blood may lead to inconclusive results. 

• Recent medical procedures - Invasive procedures or biopsies may temporarily increase cell release into bloodstream. 

How is a NextGen Liquicore CTC Comprehensive Test Done? 

The NextGen Liquicore CTC Comprehensive Test follows a systematic process to ensure accurate genetic analysis of circulating tumour cells: 

• Blood sample collection - A healthcare professional draws 8-10ml of blood from a vein in your arm using K2 EDTA tubes. 

• Sample preparation - Blood is gently mixed 8-10 times and maintained at 2-8°C during transport. 

• Cell isolation - Specialised Liquicore technology captures and isolates circulating tumour cells from your blood. 

• DNA extraction - Genetic material is carefully extracted from the isolated cancer cells. 

• Next-Generation Sequencing - Advanced NGS technology analyses the DNA for mutations and genetic alterations. 

• Data analysis - Expert pathologists interpret the genetic findings and prepare your comprehensive report. 

How Should You Prepare for a NextGen Liquicore CTC Comprehensive Test? 

Preparing for your NextGen Liquicore CTC Comprehensive Test is straightforward with minimal requirements: 

• No fasting required - You can eat and drink normally before the test. 

• Continue your medications - Do not stop cancer treatments or other prescribed medicines unless instructed by your oncologist. 

• Gather required documents - Bring your clinical history, histopathology reports, and IHC (immunohistochemistry) results. 

• Stay well-hydrated - Drink plenty of water to make blood collection easier. 

• Wear comfortable clothing - Choose clothes with sleeves that can be easily rolled up for a blood draw. 

• Inform about supplements - Tell your healthcare provider about all medications and supplements you're taking. 

Diseases that a NextGen Liquicore CTC Comprehensive Test Can Help Detect 

This advanced genetic test assists in detecting and monitoring various cancer-related health conditions: 

• Breast cancer - Monitors treatment response and detects genetic mutations in circulating breast cancer cells. 

• Prostate cancer - Tracks disease progression and identifies therapeutic targets in advanced prostate cancer. 

• Colorectal cancer - Detects MSI status and guides immunotherapy decisions for colon and rectal cancers. 

• Lung cancer - Analyses genetic alterations to guide targeted therapy selection. 

• Ovarian cancer - Monitors treatment effectiveness and genetic evolution of ovarian tumours. 

• Pancreatic cancer - Provides genetic insights for personalised treatment approaches. 

• Bladder cancer - Tracks circulating tumour cells for disease monitoring. 

• Lynch syndrome - Identifies hereditary cancer predisposition through MSI analysis. 

• Central nervous system (CNS) malignancies – Combines MRI findings and CSF (cerebrospinal fluid) analysis with circulating tumour cell detection to enhance diagnosis and monitoring of brain and spinal cancers. 

NextGen Liquicore CTC Comprehensive Test/Packages that You Can Book With Metropolis Healthcare 

The following table shows related tests and packages available to complement your cancer monitoring and genetic analysis: 

Test/Package Name	Purpose/Highlights
Tumour Mutation Burden NGS	Analyses multiple genetic mutations to guide targeted therapy decisions.
Microsatellite Instability (MSI)/HNPCC/Lynch Syndrome, PCR	Detects genetic conditions that increase cancer risk and guide treatment
Tumour/Cancer Marker Profile Test	Comprehensive panel of cancer markers for screening and monitoring
Autoimmune Encephalitis Panel Test	Diagnoses autoimmune brain inflammation conditions